Immitra Bio

Zürich, CH · 5 known investors

Immitra Bio develops an in-vivo stem cell therapy platform designed to treat rare genetic diseases, particularly severe inherited red blood cell disorders, by replacing complex transplants with single off-the-shelf treatments. The company is an ETH Zürich spin-off focused on precision medicine and gene editing approaches for genetic disease intervention.